Clinical Trial Detail

NCT ID NCT02091245
Title Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

mixed phenotype acute leukemia

acute lymphoblastic leukemia

acute myeloid leukemia

leukemia

chronic myeloid leukemia

Therapies

Selinexor

Age Groups: child

No variant requirements are available.